Cardiac Amyloidosis Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Car
Author : siddhi cmi | Published On : 03 Feb 2025
Cardiac amyloidosis is a medical condition caused by an abnormal protein called amyloid that builds up in the heart muscle. It causes the heart muscle to stiffen and limits the heart's ability to pump blood efficiently. The deposits interfere with the normal functioning of the heart and there are no specific symptoms in early stages. As the disease progresses, it can lead to heart failure, arrhythmias and sudden cardiac death. The increasing incidence of cardiovascular diseases, growing geriatric population and rising investments for developing novel therapeutic treatments are expected to drive the growth of the global cardiac amyloidosis market.
The Global Cardiac Amyloidosis Market is estimated to be valued at USD 6.12 Bn in 2024 and is expected to reach USD 11.45 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Key Takeaways
Key players operating in the cardiac amyloidosis market are Pfizer Inc, Alnylam Pharmaceuticals, Prothena Corporation PLC, PhaseBio Pharmaceuticals, Inc, GlaxoSmithKline plc.
The increasing research and development activities for developing novel therapeutics offer lucrative growth opportunities in the Cardiac Amyloidosis Market. Manufacturers are focusing on introducing therapies targeting the underlying causes to manage the disease effectively.
The cardiac amyloidosis market is expanding rapidly as major market players are emphasizing on geographic expansions to tap the growth opportunities in developing regions. Asia Pacific represents a profitable market owing to increasing healthcare expenditures and large patient pool.
Market drivers
The rising prevalence of cardiovascular diseases is a major factor driving the growth of the cardiac amyloidosis market. According to the World Health Organization, cardiovascular diseases accounted for over 17 million deaths in 2015. Amyloidosis is associated with old age and the risk increases substantially beyond the age of 65 years. As per the Population Reference Bureau, the number of Americans aged 65 and above is projected to double from 52 million to over 95 million between 2018 and 2060. The surging geriatric populationbase renders this population segment more susceptible to cardiac amyloidosis, thereby augmenting the market growth.
PEST Analysis
Political: The political landscape plays a key role in shaping research funding for rare diseases like cardiac amyloidosis. Regulations surrounding drug approval can significantly impact treatment availability.
Economic: Economic factors like rising healthcare costs and an aging population contribute to the growing economic burden of cardiac amyloidosis. This drives research into more effective and affordable therapies.
Social: Increased awareness through patient advocacy groups has helped shift social perceptions and priorities for conditions like cardiac amyloidosis. This impacts research support and quality of life support for patients.
Technological: Advanced imaging techniques and novel biomarkers now enable earlier and more accurate diagnosis of cardiac amyloidosis. New drug delivery methods and targeted therapies are also being developed to better treat the disease.
The North American region currently accounts for the largest share of the global cardiac amyloidosis market in terms of value. This can be attributed to factors like growing awareness, strong research funding, and advanced healthcare infrastructure and services in countries like the United States.
The Asia Pacific region is poised to be the fastest growing market for cardiac amyloidosis globally. This is due to massive unmet needs arising from rising incomes, lifestyle changes, and an aging population in emerging economies like China and India. Improving access to diagnosis and care is also expected to drive the cardiac amyloidosis market growth in Asia Pacific in the coming years.
Get this Report in Japanese Language: 心臓アミロイドーシス市場
Get this Report in Korean Language: 심장 아밀로이드증 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
